Huahai Pharma gains approval for lacosamide injection

Zhejiang Huahai Pharmaceutical Co., Ltd. (SSE:600521) announced that it has been granted a drug registration certificate for its Lacosamide Injection by the National Medical Products Administration. The injection, indicated for adjunctive treatment of partial-onset seizures in epileptic patients aged four years and older, is categorized as a Class 4 chemical drug. The drug was originally developed by UCB and first launched in Europe and the United States in 2008. Data suggests the domestic Lacosamide Injection market reached approximately RMB 115 million in the first half of 2024. Huahai Pharma has invested approximately RMB 28.9 million in the research and development of this product. The company believes the approval will enrich its product line and enhance its market competitiveness, positively impacting its financial performance.